<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR15">
 <label>15.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Pro</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Advani</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Brice</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Bartlett</surname>
    <given-names>NL</given-names>
   </name>
   <name>
    <surname>Rosenblatt</surname>
    <given-names>JD</given-names>
   </name>
   <name>
    <surname>Illidge</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Matous</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Ramchandren</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Fanale</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Connors</surname>
    <given-names>JM</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Sievers</surname>
    <given-names>EL</given-names>
   </name>
   <name>
    <surname>Kennedy</surname>
    <given-names>DA</given-names>
   </name>
   <name>
    <surname>Sustov</surname>
    <given-names>A</given-names>
   </name>
  </person-group>
  <article-title>Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study</article-title>
  <source>J Clin Oncol</source>
  <year>2012</year>
  <volume>30</volume>
  <fpage>2190</fpage>
  <lpage>2196</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2011.38.0402</pub-id>
  <pub-id pub-id-type="pmid">22614995</pub-id>
 </element-citation>
</ref>
